References
- The CSAT Methamphetamine Treatment Project: Moving research into the “real world.”. Journal of Psychoactive Drugs, M. D. Anglin, R. A. Rawson, 2000; 32: 135–136
- Bialer P. A. Designer drugs in the general hospital. Psychiatry in the Medically Ill 2002; 25: 231–243
- Center for Substance Abuse Treatment. Assessment and Treatment of Patients with Coexisting Mental Illness and Alcohol and Other Drug Abuse: TIP# 9. Department of Health and Human Services, Rockville, MD 1994
- Center for Substance Abuse Treatment. Substance Use Disorder Treatment for People with Physical and Cognitive Disabilities: TIP# 29. Department of Health and Human Services, Rockville, MD 1998
- Cottler L. B., Womack S. B., Compton W. M., Ben-Abdallah A. Ecstasy abuse and dependence among adolescents and young adults: Applicability and reliability of DSM-IV criteria. Hum. Psychopharmacol. Clin. Exp. 2001; 16: 599–606, [CROSSREF], [CSA]
- Daderman A. M., Fredriksson B., Kristiansson M., Nilsson L. H., Lidberg L. Violent behavior, impulsive decision-making and anterograde amnesia while intoxicated with flunitrazepam and alcohol or other drugs: A case study in forensic psychiatric patients. J. Am. Acad. Psychiatry Law 2002; 30: 328–351
- Daderman A. M., Edman G. Flunitrazepam abuse and personality characteristics in male forensic psychiatric patients. Psychiatry Research 2001; 10: 27–42, [CROSSREF]
- Freese T. E., Miotto K., Reback C. J. The effects and consequences of selected club drugs. Journal of Substance Abuse Treatment 2002; 23: 151–156, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Halpern J. H., Pope H. G. Hallucinogen persisting perception disorder: What do we know after 50 years?. Drug and Alcohol Dependence 2003; 69: 109–119, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Huber A., Ling W., Shoptaw S., Gulati V., Brethen P., Rawson R. A. Integrating treatment for methamphetamine abuse: A psychosocial perspective. Journal of Addictive Diseases 1997; 16: 41–50, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jansen K. L. R., Darracot-Cankovic R. The nonmedical use of ketamine, part two: A review of problem use and dependence. J. Psychoactive Drugs 2001; 33: 151–158, [PUBMED], [INFOTRIEVE], [CSA]
- Lim D. K. Ketamine associated psychedelic effects and dependence. Singapore Medical Journal 2003; 44(1)31–34, [PUBMED], [INFOTRIEVE], [CSA]
- Mahr G., Bishop C. L., Orringer D. J. Prolonged withdrawal from extreme gamma-hydroxybutyrate (GHB) abuse. Psychosomatics 2001; 42(5)439–440, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mansergh G., Colfax G. N., Marks G., Rader M., Guzman R., Buchbinder S. The circuit party men's health survey: Findings and implications for gay and bisexual men. American Journal of Public Health 2001; 91(6)953–958, [PUBMED], [INFOTRIEVE], [CSA]
- Maxwell J. C. The response to club drug use. Current Opinion in Psychiatry 2003; 16: 279–289, [CROSSREF]
- Maxwell J. C. (2004) Substance abuse trends in Texas— June 2004. Epidemiologic Trends in Drug Abuse: Proceedings of the Community Epidemiology Work Group. June, 2004. National Institute on Drug Abuse, Rockville, MD, Volume II
- Maxwell J. C. Party drugs: properties, prevalence, patterns, and problems. Substance Use and Misuse 2005; 40(9–10)1203–1240
- McCardle K., Luebbers S., Carter J. D., Croft R. J., Stough C. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology. 2004, http://springerlink.metapress.com(accessed April 2004)
- McDaniel C. H., Miotto K. A. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: Five case studies. Journal of Psychoactive Drugs 2001; 33(2)143–149, [PUBMED], [INFOTRIEVE], [CSA]
- McLellan A. T., Luborsky L., Woody G. E., O'Brien C. P. An improved evaluation instrument for substance abuse patients: The addiction severity index. Journal of Nervous and Mental Disease 1980; 168: 26–33, [PUBMED], [INFOTRIEVE]
- National Institute on Drug Abuse. Epidemiologic Trends in Drug Abuse, Advance Report: June 2003. National Institute on Drug Abuse, Rockville, MD 2003
- National Institute on Drug Abuse. NIDA InfoFacts: LSD, Undated, http://www.nida.nih.gov(accessed March 7, 2004)
- Rawson R. A. Treatment of Stimulant Abuse. CSAT Tip #33. Department of Health and Human Services, Rockville, MD 1998, Chair, CSAT Consensus Panel
- Rawson R. A., Gonzales R., Brethen P. Treatment of methamphetamine use disorders: An update. Journal of Substance Abuse Treatment 2002; 23: 145–150, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rawson R. A., Huber A., Brethen P. B., Obert J. L., Gulau V., Shoptaw S., Ling W. Methamphetamine and cocaine users: Differences in characteristics and treatment retention. Journal of Psychoactive Drugs 2000; 32: 233–238, [PUBMED], [INFOTRIEVE], [CSA]
- Rawson R. A., Huber A., Brethen P., Obert J. L., Gulati V., Shoptaw S., Ling W. Status of methamphetamine users 2–5 years after outpatient treatment. Journal of Addictive Diseases 2002; 21: 107–119, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Romanelli F., Smith K. M., Pomeroy C. Use of club drugs by HIV-seropositive and HIV-seronegative gay and bisexual men. Topics in HIV Medicine 2003; 11(1)25–32, [PUBMED], [INFOTRIEVE], [CSA]
- Schneir A. B., Ly B. T., Clark R. F. A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4 butanediol. J. Emerg. Med. 2001; 21(1)31–33, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Smith K. M., Larive L. L., Romanelli F. Club Drugs: Methylene dioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and γ –hydroxybutyrate. Am. J. Health-Syst. Ph. 2002; 59(11)1067–1076, [CSA]
- Taffe M. A., Davis S. A., Gutierrez T., Gold L. H. Ketamine impairs multiple cognitive domains in rhesus monkeys. Drug Alcohol Depend 2002; 68: 175–187, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Winters K. C. Treatment of Adolescents with Substance Use Disorders. CSAT Tip #32. Department of Health and Human Services, Rockville, MD 1999, (Chair, CSAT Consensus Panel)